Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic <i>Pseudomonas aeruginosa</i> Lung Infection Based on Preclinical Population Pharmacokinetic Modeling

Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic <i>Pseudomonas aeruginosa</i> Lung Infection Based on Preclinical Population Pharmacokinetic Modeling

Biofilms and infectious process may alter free antimicrobial concentrations at the site of infection. Tobramycin (TOB), an aminoglycoside used to treat lung infections caused by <i>Pseudomonas aeruginosa</i>, binds to alginate present in biofilm extracellular matrix increasing its minimu...

Full description

Bibliographic Details
Main Authors: Bruna Bernar Dias, Fernando Carreño, Victória Etges Helfer, Priscila Martini Bernardi Garzella, Daiane Maria Fonseca de Lima, Fabiano Barreto, Bibiana Verlindo de Araújo, Teresa Dalla Costa
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceutics
Subjects:
tobramycin
popPK model
<i>Pseudomonas aeruginosa</i> infection model
biofilm
microdialysis
PTA
Online Access:https://www.mdpi.com/1999-4923/14/6/1237

Internet

https://www.mdpi.com/1999-4923/14/6/1237

Similar Items